Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism

Figures & data

Table 1 Baseline characteristics of study parameters

Covariates	NPHPT	Controls	p-value
Age, years, mean ± SD	65.15±7.71	61.06±7.65	0.165
Body mass index, kg/m^2, mean ± SD	26.97±5.14	31.53±6.25	0.044
Abdominal circumference, cm, mean ± SD	93.84±11.15	100.93±12.97	0.131
Glycemia, mg/dL, mean ± SD	92±13.68	102.58±14.66	0.056
Glycated hemoglobin, %, mean ± SD	5.59±0.34	6.62±0.58	0.000
Altered blood pressure, mmHg, n (%)	8 (61.54)	11 (68.75)	0.684
Total cholesterol, mg/dL, mean ± SD	188.07±32.99	220.64±59.14	0.088
HDL-cholesterol, mg/dL, mean ± SD	50.38±15.46	49.45±12.60	0.860
LDL-cholesterol, mg/dL, mean ± SD	109.56±32.4	134.73±53.07	0.146
Triglycerides, mg/dL, median (P25–P75)**	146 (114–156)	152.49 (112.34–237.15)	0.219
Corrected calcium, mg/dL, mean ± SD*	9.28±1.05	8.28±0.45	0.002
Glomerular filtration rate, mL/min, mean ± SD	89.87±19.66	98.88±20.66	0.243
25-OH vitamin D, ng/mL, mean ± SD	35.32±8.42	26.11±8.94	0.008
PTH, pg/mL, mean ± SD	100.58±29.83	30.26±12.00	0.000
Comorbidities, n (%)	11 (84.62)	15 (93.75)	0.422
Smoking, n (%)	0	2 (12.5%)	0.186
Family history of early CAD, n (%)	2 (15.38)	0	0.104
Dyslipidemia, n (%)	9 (69.23)	13 (81.25)	0.452
Hypertension, n (%)	8 (61.54)	11 (68.75)	0.684
Diabetes mellitus, n (%)	1 (7.69)	6 (37.5)	0.062
Medications
Vitamin D replacements, n (%)	7 (53.85)	2 (12.5)	0.017
Calcium replacement, n (%)	1 (7.69)	0	0.259
Bisphosphonate, n (%)	2 (15.38)	0	0.104
Oral hypoglycemic, n (%)	0	6 (37.5)	0.013
Insulin, n (%)	0	1 (6.25)	0.359
Statin, n (%)	7 (53.85)	6 (46.15)	0.379
Angiotensin-converting enzyme inhibitor, n (%)	3 (23.08)	4 (25)	0.904
Angiotensin receptor blocker, n (%)	4 (36.36)	7 (63.64)	0.513
Calcium channel blocker, n (%)	2 (15.38)	3 (18.75)	0.811
Platelet antiaggregant, n (%)	2 (15.38)	0	0.104

Notes:

* Mean ± SD: Student’s t-test;

** Kruskal–Wallis test. Median, P50.

Abbreviations: CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NPHPT, normocalcemic primary hyperparathyroidism; P25/P50/P75, 25th, 50th, and 75th percentiles, respectively; PTH, parathyroid hormone; SD, standard deviation.

Table 2 Association between coronary calcium score and NPHPT

Factor	n (%)		OR (95% CI)	p-value
	CCS >0	CCS =0
NPHPT
No	10 (62.5)	6 (37.5)	Reference	NA
Yes	4 (30.77)	9 (69.23)	0.27 (0.05–1.26)	0.095
Total	14 (48.28)	15 (51.72)	NA	NA

Abbreviations: CCS, coronary calcium score; CI, confidence interval; NPHPT, normocalcemic primary hyperparathyroidism; NA, not available; OR, odds ratio; PTH, parathyroid hormone.

Table 3 Association between coronary calcium score and the condition of NPHPT adjusted for potential confounders*

Calcium score	OR	p-value	ORadjusted	p-value
NPHPT
No	Reference	NA	Reference	NA
Yes	0.27	0.096	1.64 (0.1–26.43)	0.726

Note:

* Adjusted for covariates such as body mass index, glycated hemoglobin, and total cholesterol.

Abbreviations: NA, not available; NPHPT, normocalcemic primary hyperparathyroidism; OR, odds ratio.